Clinical Trials Browser

Phase 2 × Small Cell Lung Carcinoma × surufatinib × Clear all

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Phase 2 Completed

Small Cell Lung Carcinoma

NCT05595889 2022-11-29

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma